Dihydropyrimidine dehydrogenase gene (DPYD) polymorphism among pts with 5-FU/capecitabine (CAP)-related adverse events (AEs): Experience of 2 decades.
Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 2576-2576
10.1200/jco.2018.36.15_suppl.2576